Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Amicus Therapeutics (FOLD) over the last 6 years, with Dec 2024 value amounting to -$0.18.

  • Amicus Therapeutics' EPS (Weighted Average and Diluted) rose 400.00% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.04, marking a year-over-year increase of 88.24%. This contributed to the annual value of -$0.18 for FY2024, which is 64.71% up from last year.
  • Latest data reveals that Amicus Therapeutics reported EPS (Weighted Average and Diluted) of -$0.18 as of FY2024, which was up 64.71% from -$0.51 recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.18 in FY2024 and a low of -$1.07 during FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.50, with a median of -$0.51 in 2023.
  • Data for Amicus Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 64.71% (in 2024) over the last 5 years.
  • Over the past 5 years, Amicus Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.07 in 2020, then climbed by 14.02% to -$0.92 in 2021, then grew by 10.87% to -$0.82 in 2022, then surged by 37.80% to -$0.51 in 2023, then spiked by 64.71% to -$0.18 in 2024.